OncoTargets and Therapy (Mar 2020)

Serum Platelet-Derived Growth Factor Is Significantly Lower in Patients with Lung Cancer and Continued to Decrease After Platinum-Based Chemotherapy

  • Ma R,
  • Yang Q,
  • Cao S,
  • Liu S,
  • Cao H,
  • Xu H,
  • Wu J,
  • Feng J

Journal volume & issue
Vol. Volume 13
pp. 1883 – 1892

Abstract

Read online

Rong Ma,1,* Qing Yang,2,* Shengya Cao,2 Siwen Liu,1 Haixia Cao,1 Heng Xu,3 Jianzhong Wu,1 Jifeng Feng1 1Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, People’s Republic of China; 2Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, People’s Republic of China; 3Laboratory of Pharmaceutical Chemistry, Jiangsu Province Institute of Materia Medica, Nanjing Tech University, Nanjing, Jiangsu 210000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jianzhong Wu; Jifeng FengResearch Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, No. 7 Building, 42 BaiZiTing Road, Nanjing, Jiangsu 210000, People’s Republic of ChinaEmail [email protected]; [email protected]: This study aimed to investigate the diagnosis and prediction of serum platelet-derived growth factor (PDGF) level in patients with lung cancer (LC).Methods: Serum concentrations of PDGF-AA and PDGF-AB/BB were determined via Luminex assay in 210 patients with non-small cell lung cancer (NSCLC), 33 patients with small cell lung cancer (SCLC), and 168 healthy controls.Results: The serum levels of PDGF-AA and PDGF-AB/BB were lower in patients with NSCLC (P < 0.05) and SCLC (P < 0.05), compared to healthy controls. The concentration of PDGF-AA or PDGF-AB/BB continued to markedly decrease in NSCLC after therapy with platinum-based chemotherapy (P < 0.05). The median survival times were 29 and 38 months in patients with NSCLC who received PDGF-AA < 30 ng/mL and PDGF-AA ≥ 30 ng/mL (P = 0.0078), and 26 and 38 months in patients with NSCLC who received PDGF-AB/BB < 42 ng/mL and PDGF-AB/BB ≥ 42 ng/mL (P = 0.0001), respectively. At the individual protein level, PDGF-AA and PDGF-AB/BB had better diagnostic values for NSCLC (AUC = 0.905, AUC = 0.922, respectively).Conclusion: Serum PDGF may be a potential biomarker for diagnosis of patients with NSCLC and SCLC. However, the prognostic value of serum PDGF in patients with NSCLC harboring mutations and different therapies requires additional investigation.Keywords: PDGF-AA, PDGF-AB/BB, chemotherapy, response, lung cancer

Keywords